Testing effectiveness (Phase 2)UnknownNCT04965519What this trial is testingRC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesWho this might be right forGynecological Malignancy RemeGen Co., Ltd. 120
Testing effectiveness (Phase 2)Study completedNCT00479674What this trial is testingPhase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast CancerWho this might be right forBreast Cancer Duke University 41
Not applicableLooking for participantsNCT05378204What this trial is testingStudy Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.Who this might be right forBreast Cancer Institut Claudius Regaud 120
Not applicableStudy completedNCT01446185What this trial is testingTreatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer PatientsWho this might be right forBreast Cancer Genomic Health®, Inc. 100
Not applicableLooking for participantsNCT07101081What this trial is testingGYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian CohortWho this might be right forGynaecological Cancers AstraZeneca 350
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07273981What this trial is testingZanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJCWho this might be right forGastric/Gastroesophageal Junction Adenocarcinoma Xijing Hospital 30
Testing effectiveness (Phase 2)Study completedNCT00944047What this trial is testingEvaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 ExpressionWho this might be right forBreast Cancer University of Kansas Medical Center 32
Not applicableUnknownNCT06243432What this trial is testingEstrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast CancerWho this might be right forAdvanced Breast Carcinoma Fondazione Policlinico Universitario Agostino Gemelli IRCCS 600
Testing effectiveness (Phase 2)Ended earlyNCT04168931What this trial is testingTrastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTCWho this might be right forGastric Cancer Stage IV AC Camargo Cancer Center 5
Post-approval studies (Phase 4)Looking for participantsNCT07195344What this trial is testingStudy Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.Who this might be right forLocally Advanced or Metastatic Breast Cancers Institut Claudius Regaud 210
Not applicableLooking for participantsNCT07331506What this trial is testingValidation of the Oncoliq Test for the Early Detection of Breast Cancer.Who this might be right forBreast Cancer DetectionBreast Cancer Early Stage Breast Cancer (Stage 1-3)Breast Cancer Female+5 more Oncoliq US Inc 300
Not applicableLooking for participantsNCT03827317What this trial is testingHERPET- A Novel PET Imaging Study of HER2 in Breast CancerWho this might be right forBreast Cancer Imperial College London 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05546268What this trial is testingStudy of Oral MRT-2359 in Selected Cancer PatientsWho this might be right forNSCLCSCLCHigh Grade Neuroendocrine Cancer+5 more Monte Rosa Therapeutics, Inc 174
Not applicableStudy completedNCT05412459What this trial is testing99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted TherapyWho this might be right forHER2-positive Breast CancerFemale Tomsk National Research Medical Center of the Russian Academy of Sciences 15
Testing effectiveness (Phase 2)Looking for participantsNCT06656624What this trial is testingEfficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)Who this might be right forAdvanced Breast Cancer The First Affiliated Hospital with Nanjing Medical University 190
Early research (Phase 1)Study completedNCT03255070What this trial is testingA Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)Who this might be right forBreast NeoplasmsGastric NeoplasmSolid Tumors Ambrx, Inc. 106
Not applicableStudy completedNCT01934478What this trial is testingRadiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast CancerWho this might be right forHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast Qingdao Central Hospital 5
Not applicableLooking for participantsNCT06289517What this trial is testingPET Imaging of 68Ga-Her2-affibody in Tumors with High Her2 ExpressionWho this might be right forNeoplasms Peking University First Hospital 30
Not applicableLooking for participantsNCT07030569What this trial is testingRADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 StudyWho this might be right forRadiomicRadiomicsBreast Cancer Metastatic+13 more Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 500
Not applicableEnrolling By InvitationNCT07454941What this trial is testingArtificial Intelligence-assisted HER2 Expression Assessment in Urothelial Carcinoma Based on Imaging-pathology OmicsWho this might be right forUrothelial Carcinoma (UC)HER2Diagnostic Cancer Institute and Hospital, Chinese Academy of Medical Sciences 4,000